We are trying to move into an electronic environment in the review process, and that will save us money, such as on storage costs for paper. A drug submission is quite enormous, so to remove those storage costs is substantial. It also saves the industry. It fits into the idea of reducing the burden.
On October 18th, 2012. See this statement in context.